Development of a LC–MS/MS methodology for the monitoring of the antichagasic drug benznidazole in human urine

Martínez, Noelia A.; Marson, María Elena; Mastrantonio, Guido; Raba, Julio; Cerutti, Soledad

doi:10.1016/j.talanta.2014.08.040

Cited by 7 publications

(4 citation statements)

References 39 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LOD between 0.04 and 0.14 μg/mL and RSD% between 1.3 and 10% were obtained, with recoveries from 70 to 97%. Recently, Martínez et al have published an analytical procedure to determine BNZ in urine by UHPLC–MS/MS with a simple sample pretreatment consisting of a LLE with dichloromethane . The methodology is quick, reproducible, and selective but, although is sensitive, the detection limit (0.75 μg/mL) resulted to be similar to others previously published in the literature due to a serious matrix effect (90% of signal suppression), which affected the ESI‐MS/MS detector.…”

Section: Introductionmentioning

confidence: 61%

Development of an ionic‐liquid‐based dispersive liquid–liquid microextraction method for the determination of antichagasic drugs in human breast milk: Optimization by central composite design

Padró

Vidal

Echevarria

et al. 2015

J of Separation Science

View full text Add to dashboard Cite

Chagas disease constitutes a major public health problem in Latin America. Human breast milk is a biological sample of great importance for the analysis of therapeutic drugs, as unwanted exposure through breast milk could result in pharmacological effects in the nursing infant. Thus, the goal of breast milk drug analysis is to inquire to which extent a neonate may be exposed to a drug during lactation. In this work, we developed an analytical technique to quantify benznidazole and nifurtimox (the two antichagasic drugs currently available for medical treatment) in human breast milk, with a simple sample pretreatment followed by an ionic‐liquid‐based dispersive liquid–liquid microextraction combined with high‐performance liquid chromatography and UV detection. For this technique, the ionic liquid 1‐octyl‐3‐methylimidazolium hexafluorophosphate has been used as the “extraction solvent.” A central composite design was used to find the optimum values for the significant variables affecting the extraction process: volume of ionic liquid, volume of dispersant solvent, ionic strength, and pH. At the optimum working conditions, the average recoveries were 77.5 and 89.7%, the limits of detection were 0.06 and 0.09 μg/mL and the interday reproducibilities were 6.25 and 5.77% for benznidazole and nifurtimox, respectively. The proposed methodology can be considered sensitive, simple, robust, accurate, and green.

show abstract

Section: Introductionmentioning

confidence: 61%

Development of an ionic‐liquid‐based dispersive liquid–liquid microextraction method for the determination of antichagasic drugs in human breast milk: Optimization by central composite design

Padró

Vidal

Echevarria

et al. 2015

J of Separation Science

View full text Add to dashboard Cite

show abstract

“…The LC-MS/MS methods described in the literature give the results of an analytical run of 5.0 min with a large volume of biological matrix (2.5 ml urine) and a high volume of organic extraction solvent (2.5 ml dichloromethane), for a linear range from 10 to 50,000 ng · ml −1 ( 14 ), and an analytical run of 3.0 min with a small volume of biological matrix (50 µl serum) and a small volume of organic extraction solvent (250 µl of ethyl acetate), for a linear range from 100 to 3,000 ng · ml −1 ( 8 ). The method described in this article uses whole blood as the biological matrix at small volumes, a 5.0-min analytical run, and 1.7 ml dichloromethane in the extraction procedure, with a linear range of 50 to 20,000 ng · ml −1 .…”

Section: Discussionmentioning

confidence: 99%

“…PK parameters are assessed using bioanalytical methods for the quantification of drugs in a biological matrix obtained by sampling in a clinical setting. There are a few methods reported in the literature for BNZ quantification in different matrices (tissues, plasma, serum, urine, and milk), notably differential pulse polarography high-performance liquid chromatography (HPLC) with ultraviolet detection ( 4 , 11 , 12 ), ultrahigh-performance liquid chromatography (UHPLC) with ultraviolet detection ( 13 ), and liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) ( 5 , 14 ).…”

Section: Introductionmentioning

confidence: 99%

Dried Blood Spot Technique-Based Liquid Chromatography-Tandem Mass Spectrometry Method as a Simple Alternative for Benznidazole Pharmacokinetic Assessment

Bedor

Bedor²,

Silva

et al. 2018

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…Various analytical methods have been used to determine and quantify BZN in various samples. Most of these methods are based on chromatography [13,14,15,16,17,18,19,20] or spectrophotometry [21]. In this sense, electroanalytical methods have received substantial attention because of their reasonable accuracy and precision.…”

Section: American Countriesmentioning

confidence: 99%

Differential pulse voltammetric determination of benznidazole loaded in nanostructured lipid carriers and urine**

et al. 2023

View full text Add to dashboard Cite

Benznidazole (BZN) is the first‐choice drug for treating Chagas disease (CD). However, it is not ideal for this purpose as it is highly toxic and has irregular pharmacokinetics due to factors such as its low aqueous solubility. These factors necessitate the development of reliable and effective alternative methods for the analytical determination of BZN in biological and pharmaceutical samples. In this context, we present a new electroanalytical method for quantifying BZN using differential pulse voltammetry (DPV) and a glassy carbon electrode (GCE). This method was applied to urine and a pharmaceutical formulation of BZN incorporated into nanostructured lipid carriers (NLC‐BZN). The proposed method provided a linear analytical range of 1.00–10.6 μmol L−1 (R=0.999), with a detection limit of 0.044 μmol L−1 and a quantification limit of 0.13 μmol L−1. The relative standard deviation of the intra‐day and inter‐day precision was below 2.50 %. Through interference studies, the methodology proved to be selective for BZN, because there was no significant potential interference in any of the samples. The recovery tests showed that the accuracy was within the limits recommended in the literature. Therefore, the developed DPV/GCE method can be successfully applied as an alternative method for detecting BZN in NLC‐BZN pharmaceutical formulations and human urine.

show abstract

Development of a LC–MS/MS methodology for the monitoring of the antichagasic drug benznidazole in human urine

Cited by 7 publications

References 39 publications

Development of an ionic‐liquid‐based dispersive liquid–liquid microextraction method for the determination of antichagasic drugs in human breast milk: Optimization by central composite design

Development of an ionic‐liquid‐based dispersive liquid–liquid microextraction method for the determination of antichagasic drugs in human breast milk: Optimization by central composite design

Dried Blood Spot Technique-Based Liquid Chromatography-Tandem Mass Spectrometry Method as a Simple Alternative for Benznidazole Pharmacokinetic Assessment

Differential pulse voltammetric determination of benznidazole loaded in nanostructured lipid carriers and urine**

Contact Info

Product

Resources

About